141 citations
,
May 2007 in “Cancer Research” CD34 is crucial for skin tumor development in mice.
26 citations
,
February 2016 in “Respiratory Medicine” Auto-antibody testing is a useful but not definitive tool in diagnosing interstitial lung diseases, and using a specific algorithm could make testing more cost-effective.
October 2019 in “Al Mustansiriyah Journal of Pharmaceutical Sciences” The CTLA-4 gene polymorphism does not affect polycystic ovarian syndrome.
11 citations
,
August 2010 in “Developmental neurobiology” Ptprq has multiple forms that change during inner ear development.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
16 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.
2 citations
,
August 2016 in “Journal of Investigative Dermatology” November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
1 citations
,
January 2022 in “Dermatology Research and Practice” Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.
16 citations
,
November 2005 in “Journal of Clinical Pathology” CD1d expression in scalp skin and hair follicles changes with the hair cycle and may help protect against microbes.
3 citations
,
May 2018 in “Journal of Cosmetic Dermatology” Biopsy can differentiate between alopecia areata and androgenic alopecia, and if more information is needed, testing for CD3 and CD8 can help.
19 citations
,
July 1997 in “British Journal of Dermatology” LHTric-1 is a specific antibody useful for studying hair and nail formation.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” CD25+ CD4+ Tregs and certain plasma proteins are linked to hair loss.
72 citations
,
September 1997 in “Journal of Investigative Dermatology” May 2023 in “The Journal of Immunology” BST2 is a key marker for hair loss disease alopecia areata.
1 citations
,
May 2020 in “Beilstein Journal of Organic Chemistry” Scientists made a sensor that can detect a specific type of RNA related to androgen receptors quickly and accurately.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
January 2016 in “Human & Experimental Toxicology” A specific DNA sequence caused hair loss in male mice by activating immune cells and increasing a certain immune signal.
1 citations
,
September 2022 Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
3 citations
,
January 2017 in “Acta Dermato Venereologica” Lipid-antigen stimulation may play a role in folliculotropic mycosis fungoides.
March 2026 in “European journal of ecology, biology and agriculture.” Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.
1 citations
,
October 2023 in “PROTOPLASMA”
31 citations
,
October 2018 in “Frontiers in Cell and Developmental Biology” The conclusion is that CD90 is not a specific marker for fibroblast subtypes and better methods are needed to identify them.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
September 2024 in “Annals of Dermatology” A new diagnostic model can help better diagnose and understand Alopecia Areata.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
November 2025 in “Journal of Investigative Dermatology” PCFCL may have unrecognized subtypes and needs more research.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.